Pharmaceuticals
Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.” Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest […]
Read More
Trump tariff fallout: Some industries grapple with lingering effects one year later
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off a wave of economic and political uncertainty, some companies are still feeling the effects. While some industries have emerged largely unscathed — having weathered twists and turns of several tariff iterations — others, such as retail, automotive, […]
Read More
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned. Patented medications and their active ingredients would be hit with a 100% tariff, according to a draft of the document obtained by […]
Read More
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly‘s rival pill that was approved this week, Novo Nordisk said Thursday. Oral Wegovy demonstrated “significantly greater mean weight loss” than orforglipron, which Lilly will sell under the […]
Read More
Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
Michael Siluk | UCG | Universal Images Group | Getty Images Novo Nordisk rose as much as 4% after England’s drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major […]
Read More
How Ireland became dependent on big pharma — and the risks ahead
In just 50 years, Ireland has become the world’s third largest exporter of pharmaceuticals, with medicines now making up about 20% of Ireland’s GDP. So how did Ireland become so tied to the pharma industry — and is that reliance at risk amid tariffs, patent cliffs and geopolitical tension? Ireland manufactures some of the world’s […]
Read More
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Texas, Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday. Centessa is one of several companies working […]
Read More
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, “predictable” monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two […]
Read More
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake | Reuters BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. The agreement will give Insilico […]
Read More
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
AstraZeneca‘s stock jumped nearly 5% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift […]
Read More